Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 6/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NNMT | P40261 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL983160 | 0.82 | PLAU (0.37) | OPRK1HTTSMN1; SMN2PLAUALDH1A1 | |
| SCHEMBL427374 | 0.82 | SMN1; SMN2 (0.46) | OPRK1SMN1; SMN2PLAUALDH1A1HSD17B10 | |
| SCHEMBL4492180 | 0.81 | CASP1 (0.49) | HTTPLAUNNMT | |
| Hydrochloric Acid SCHEMBL21457860 | 0.81 | SMN1; SMN2 (0.44) | OPRK1SMN1; SMN2PLAUALDH1A1HSD17B10 | |
| SCHEMBL4482054 | 0.81 | SMN1; SMN2 (0.44) | OPRK1SMN1; SMN2PLAUALDH1A1HSD17B10 | |
| SCHEMBL30036961 | 0.81 | CASP1 (0.49) | HTTPLAUNNMT | |
| SCHEMBL19209859 | 0.80 | ALDH1A1 (0.33) | OPRK1PLAUALDH1A1KDR | |
| SCHEMBL15999441 | 0.80 | OPRK1 (0.46) | OPRK1SMN1; SMN2KDRNNMT | |
| SCHEMBL733159 | 0.80 | OPRK1 (0.49) | OPRK1 | |
| SCHEMBL15999462 | 0.80 | ALDH1A1 (0.56) | OPRK1HTTSMN1; SMN2PLAUALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421226-B2 | Heteroaryl compounds as necrosis inhibitors, composition and method using the same | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2025-09-23 | — | — | US | disclosed |
| WO-2025125688-A2 | NOVEL COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2025-06-19 | — | — | WO | disclosed |
| US-20240409538-A1 | SUBSTITUTED TRIAZOLOHETEROARYL COMPOUNDS AS USP1 INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI), INC. (CN) | 2024-12-12 | — | — | US | disclosed |
| US-20240190904-A1 | Heteroaryl compounds as inhibitors of RIP2 kinase, composition and application thereof | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2024-06-13 | — | — | US | disclosed |
| EP-4322947-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF RIP2 KINASE, COMPOSITION AND APPLICATION THEREOF | Accro Bioscience (HK) Limited (HK) | 2024-02-21 | — | — | EP | disclosed |
| EP-3559007-B1 | SULFONAMIDE COMPOUNDS HAVING TNAP INHIBITORY ACTIVITY | DAIICHI SANKYO CO LTD (JP) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023066299-A1 | SUBSTITUTED TRIAZOLOHETEROARYL COMPOUNDS AS USP1 INHIBITORS AND THE USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) | 2023-04-27 | — | — | WO | disclosed |
| WO-2022192760-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF RIP2 KINASE, COMPOSITION AND APPLICATION THEREOF | ACCRO BIOSCIENCE (HK) LIMITED (CN) | 2022-09-15 | — | — | WO | disclosed |
| US-20220112188-A1 | HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME | ACCRO BIOSCIENCE (HK) LIMITED (HK) | 2022-04-14 | — | — | US | disclosed |
| CN-110167946-B | Sulfonamide compounds having TNAP inhibitory activity | 第一三共株式会社 | 2022-04-08 | — | — | CN | disclosed |
| US-20080269243-A1 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080255145-A1 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255145-A1 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255145-A1 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-7354944-B2 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7354944-B2 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-7354944-B2 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1809282-A2 | THIADIAZOLE COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060154961-A1 | Thiadiazole compounds and methods of use | AMGEN INC. | 2006-07-13 | — | — | US | disclosed |
| WO-2006044860-A2 | THIADIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421226-B2 | Heteroaryl compounds as necrosis inhibitors, composition and method using the same | TNF, LITAF, PNLIP | OPRK1 2166/4885PTGDR2 1631/4885TSHR 3643/4885 |
| US-20080255145-A1 | Thiadiazole compounds and methods of use | PDK2, PDK1, PANK2 | OPRK1 2362/4885PTGDR2 334/4885TSHR 1126/4885 |
| US-20220112188-A1 | HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME | TNF, LITAF, PNLIP | OPRK1 2166/4885PTGDR2 1631/4885TSHR 3643/4885 |
| US-20240409538-A1 | SUBSTITUTED TRIAZOLOHETEROARYL COMPOUNDS AS USP1 INHIBITORS AND THE USE THEREOF | USP1, USP2, USP3 | OPRK1 2573/4885PTGDR2 696/4885TSHR 2998/4885 |
| US-20080269243-A1 | Thiadiazole compounds and methods of use | PDK2, PDK1, PANK2 | OPRK1 2362/4885PTGDR2 334/4885TSHR 1126/4885 |
| US-20060154961-A1 | Thiadiazole compounds and methods of use | PDK2, PDK1, PANK2 | OPRK1 2362/4885PTGDR2 334/4885TSHR 1126/4885 |
| US-20240190904-A1 | Heteroaryl compounds as inhibitors of RIP2 kinase, composition and application thereof | RIPK2, RIPK1, RIPK3 | OPRK1 3615/4885PTGDR2 3094/4885TSHR 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.